Page last updated: 2024-10-26

dipyridamole and Bladder Cancer

dipyridamole has been researched along with Bladder Cancer in 4 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Research Excerpts

ExcerptRelevanceReference
"The present study was performed to investigate the capability of gemcitabine and pemetrexed to synergistically interact with respect to cytotoxicity and apoptosis in T24 and J82 bladder cancer cells, and to establish a correlation between drug activity and gene expression of selected genes in tumour samples."9.12In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. ( Curigliano, G; Danesi, R; De Braud, F; De Cobelli, O; Del Tacca, M; Giovannetti, E; Mey, V; Nannizzi, S; Pece, S; Verweij, F, 2006)
"The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model."7.68Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. ( Donaldson, JT; Keane, TE; Norwood, DL; Poulton, SH; Rosner, G; Walther, PJ, 1990)
"The present study was performed to investigate the capability of gemcitabine and pemetrexed to synergistically interact with respect to cytotoxicity and apoptosis in T24 and J82 bladder cancer cells, and to establish a correlation between drug activity and gene expression of selected genes in tumour samples."5.12In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. ( Curigliano, G; Danesi, R; De Braud, F; De Cobelli, O; Del Tacca, M; Giovannetti, E; Mey, V; Nannizzi, S; Pece, S; Verweij, F, 2006)
"The antitumor efficacy and host toxicity of dipyridamole (DP), methotrexate (MTX) and cisplatin (CDDP) alone and combined were evaluated in a nude mouse supported human bladder cancer model."3.68Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers. ( Donaldson, JT; Keane, TE; Norwood, DL; Poulton, SH; Rosner, G; Walther, PJ, 1990)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (75.00)18.2507
2000's1 (25.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mey, V1
Giovannetti, E1
De Braud, F1
Nannizzi, S1
Curigliano, G1
Verweij, F1
De Cobelli, O1
Pece, S1
Del Tacca, M1
Danesi, R1
Witjes, JA1
vd Meijden, AP1
Doesburg, W1
Debruyne, FM1
Keane, TE2
Rosner, GL1
Gingrich, JR1
Poulton, SH2
Walther, PJ2
Rosner, G1
Donaldson, JT1
Norwood, DL1

Trials

1 trial available for dipyridamole and Bladder Cancer

ArticleYear
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
    British journal of cancer, 2006, Aug-07, Volume: 95, Issue:3

    Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis

2006

Other Studies

3 other studies available for dipyridamole and Bladder Cancer

ArticleYear
Influence of fibrin clot inhibitors on the efficacy of intravesical Bacillus Calmette-Guérin in the treatment of superficial bladder cancer. The Dutch Southeast Cooperative Urological Group.
    European urology, 1993, Volume: 23, Issue:3

    Topics: Administration, Intravesical; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; BCG

1993
The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer.
    The Journal of urology, 1991, Volume: 146, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cisplatin; Dipyridamole; Disease

1991
Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers.
    The Journal of urology, 1990, Volume: 144, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Di

1990